array(40) {
  [0]=>
  string(4) "1943"
  ["article_id"]=>
  string(4) "1943"
  [1]=>
  string(86) "Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application"
  ["article_title"]=>
  string(86) "Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application"
  [2]=>
  string(150) "NEWTON, Mass., March 14, 2019 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced th"
  ["short_description"]=>
  string(150) "NEWTON, Mass., March 14, 2019 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced th"
  [3]=>
  string(247) "NEWTON, Mass., March 14, 2019 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act..."
  ["description"]=>
  string(247) "NEWTON, Mass., March 14, 2019 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(177) "https://www.drugs.com/nda/selinexor_190314.html?utm_source=ddc&utm_medium=rss&utm_campaign=Karyopharm+Announces+FDA+Extension+of+Review+Period+for+Selinexor+New+Drug+Application"
  ["blog_url"]=>
  string(177) "https://www.drugs.com/nda/selinexor_190314.html?utm_source=ddc&utm_medium=rss&utm_campaign=Karyopharm+Announces+FDA+Extension+of+Review+Period+for+Selinexor+New+Drug+Application"
  [15]=>
  string(19) "2019-03-14 12:03:17"
  ["add_date"]=>
  string(19) "2019-03-14 12:03:17"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:51"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5339"
  ["article_id"]=>
  string(4) "5339"
  [1]=>
  string(52) "The MENA Physical Medicine & Rehabilitation Congress"
  ["article_title"]=>
  string(52) "The MENA Physical Medicine & Rehabilitation Congress"
  [2]=>
  string(162) "&#nl&#nl&#nl&#nlThe MENA Physical Medicine & Rehabilitation Congress, will attract over 400 health professionals working within physical medicine and reha"
  ["short_description"]=>
  string(162) "&#nl&#nl&#nl&#nlThe MENA Physical Medicine & Rehabilitation Congress, will attract over 400 health professionals working within physical medicine and reha"
  [3]=>
  string(522) "&#nl&#nl&#nl&#nlThe MENA Physical Medicine & Rehabilitation Congress, will attract over 400 health professionals working within physical medicine and rehabilitation.&#nl &#nlThe congress will cover different areas in Rehabilitation and Physical Medicine including Stroke Rehabilitation, Neurological Rehabilitation, Sports Medicine, Paediatric Rehabilitation, Spinal Cord Injuries, musculoskeletal rehabilitation, Brain Injuries, Advanced Technology in Rehabilitation Medicine and more in focused sessions for e..."
  ["description"]=>
  string(522) "&#nl&#nl&#nl&#nlThe MENA Physical Medicine & Rehabilitation Congress, will attract over 400 health professionals working within physical medicine and rehabilitation.&#nl &#nlThe congress will cover different areas in Rehabilitation and Physical Medicine including Stroke Rehabilitation, Neurological Rehabilitation, Sports Medicine, Paediatric Rehabilitation, Spinal Cord Injuries, musculoskeletal rehabilitation, Brain Injuries, Advanced Technology in Rehabilitation Medicine and more in focused sessions for e..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(82) "https://www.pharmiweb.com/event/the-mena-physical-medicine-rehabilitation-congress"
  ["blog_url"]=>
  string(82) "https://www.pharmiweb.com/event/the-mena-physical-medicine-rehabilitation-congress"
  [15]=>
  string(19) "2019-03-14 10:36:45"
  ["add_date"]=>
  string(19) "2019-03-14 10:36:45"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:28"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4488"
  ["article_id"]=>
  string(4) "4488"
  [1]=>
  string(55) "Saudi International Laboratory and Diagnostics Congress"
  ["article_title"]=>
  string(55) "Saudi International Laboratory and Diagnostics Congress"
  [2]=>
  string(162) "&#nl&#nl&#nl&#nlSaudi International Laboratory and Diagnostics Congress will gather experts in the field of clinical laboratory and diagnostics and will discuss l"
  ["short_description"]=>
  string(162) "&#nl&#nl&#nl&#nlSaudi International Laboratory and Diagnostics Congress will gather experts in the field of clinical laboratory and diagnostics and will discuss l"
  [3]=>
  string(512) "&#nl&#nl&#nl&#nlSaudi International Laboratory and Diagnostics Congress will gather experts in the field of clinical laboratory and diagnostics and will discuss latest advancements and international guidelines regarding key issues such as efficient lab management tools, quality indicators and guidelines, total lab automation and its impact on efficiency and patient safety, the fundamental role of effective diagnostic tools in blood banks, managing a successful Point of Care Testing Unit, and hot topics i..."
  ["description"]=>
  string(512) "&#nl&#nl&#nl&#nlSaudi International Laboratory and Diagnostics Congress will gather experts in the field of clinical laboratory and diagnostics and will discuss latest advancements and international guidelines regarding key issues such as efficient lab management tools, quality indicators and guidelines, total lab automation and its impact on efficiency and patient safety, the fundamental role of effective diagnostic tools in blood banks, managing a successful Point of Care Testing Unit, and hot topics i..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(89) "https://www.pharmiweb.com/event/saudi-international-laboratory-and-diagnostics-congress-1"
  ["blog_url"]=>
  string(89) "https://www.pharmiweb.com/event/saudi-international-laboratory-and-diagnostics-congress-1"
  [15]=>
  string(19) "2019-03-14 10:34:34"
  ["add_date"]=>
  string(19) "2019-03-14 10:34:34"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:32:21"
  ["create_at"]=>
  string(19) "2019-09-14 14:32:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2015"
  ["article_id"]=>
  string(4) "2015"
  [1]=>
  string(148) "Atossa Genetics Announces FDA Approval of Oral Endoxifen for "Expanded Access" as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient"
  ["article_title"]=>
  string(148) "Atossa Genetics Announces FDA Approval of Oral Endoxifen for "Expanded Access" as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient"
  [2]=>
  string(150) "SEATTLE, March 14, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeut"
  ["short_description"]=>
  string(150) "SEATTLE, March 14, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeut"
  [3]=>
  string(250) "SEATTLE, March 14, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that..."
  ["description"]=>
  string(250) "SEATTLE, March 14, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/atossa-genetics-announces-fda-approval-oral-endoxifen-expanded-access-post-mastectomy-u-s-breast-18094.html?utm_source=ddc&utm_medium=rss&utm_campaign=Atossa+Genetics+Announces+FDA+Approval+of+Oral+Endoxifen+for+%22Expanded+Access%22+as+Post-Mastectomy+Treatment"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/atossa-genetics-announces-fda-approval-oral-endoxifen-expanded-access-post-mastectomy-u-s-breast-18094.html?utm_source=ddc&utm_medium=rss&utm_campaign=Atossa+Genetics+Announces+FDA+Approval+of+Oral+Endoxifen+for+%22Expanded+Access%22+as+Post-Mastectomy+Treatment"
  [15]=>
  string(19) "2019-03-14 09:03:52"
  ["add_date"]=>
  string(19) "2019-03-14 09:03:52"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2016"
  ["article_id"]=>
  string(4) "2016"
  [1]=>
  string(102) "DermBiont Begins Phase 2 Clinical Trial for Athlete's Foot with a Live Bacterial Topical Probiotic"
  ["article_title"]=>
  string(102) "DermBiont Begins Phase 2 Clinical Trial for Athlete's Foot with a Live Bacterial Topical Probiotic"
  [2]=>
  string(150) "BOSTON, March 13, 2019 /PRNewswire-PRWeb/ -- DermBiont, an early stage biopharmaceutical company dedicated to the discovery and development of live ba"
  ["short_description"]=>
  string(150) "BOSTON, March 13, 2019 /PRNewswire-PRWeb/ -- DermBiont, an early stage biopharmaceutical company dedicated to the discovery and development of live ba"
  [3]=>
  string(249) "BOSTON, March 13, 2019 /PRNewswire-PRWeb/ -- DermBiont, an early stage biopharmaceutical company dedicated to the discovery and development of live bacterial products for the treatment of skin diseases has initiated a clinical trial with its lead..."
  ["description"]=>
  string(249) "BOSTON, March 13, 2019 /PRNewswire-PRWeb/ -- DermBiont, an early stage biopharmaceutical company dedicated to the discovery and development of live bacterial products for the treatment of skin diseases has initiated a clinical trial with its lead..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(280) "https://www.drugs.com/clinical_trials/dermbiont-begins-phase-2-clinical-trial-athlete-s-foot-live-bacterial-topical-probiotic-18102.html?utm_source=ddc&utm_medium=rss&utm_campaign=DermBiont+Begins+Phase+2+Clinical+Trial+for+Athlete%27s+Foot+with+a+Live+Bacterial+Topical+Probiotic"
  ["blog_url"]=>
  string(280) "https://www.drugs.com/clinical_trials/dermbiont-begins-phase-2-clinical-trial-athlete-s-foot-live-bacterial-topical-probiotic-18102.html?utm_source=ddc&utm_medium=rss&utm_campaign=DermBiont+Begins+Phase+2+Clinical+Trial+for+Athlete%27s+Foot+with+a+Live+Bacterial+Topical+Probiotic"
  [15]=>
  string(19) "2019-03-14 07:03:17"
  ["add_date"]=>
  string(19) "2019-03-14 07:03:17"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2017"
  ["article_id"]=>
  string(4) "2017"
  [1]=>
  string(69) "Moleculin Files with FDA for Expedited Approval Pathway for Annamycin"
  ["article_title"]=>
  string(69) "Moleculin Files with FDA for Expedited Approval Pathway for Annamycin"
  [2]=>
  string(150) "HOUSTON, TX / ACCESSWIRE / March 13, 2019 / Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical sta"
  ["short_description"]=>
  string(150) "HOUSTON, TX / ACCESSWIRE / March 13, 2019 / Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical sta"
  [3]=>
  string(247) "HOUSTON, TX / ACCESSWIRE / March 13, 2019 / Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant..."
  ["description"]=>
  string(247) "HOUSTON, TX / ACCESSWIRE / March 13, 2019 / Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(218) "https://www.drugs.com/clinical_trials/moleculin-files-fda-expedited-approval-pathway-annamycin-18088.html?utm_source=ddc&utm_medium=rss&utm_campaign=Moleculin+Files+with+FDA+for+Expedited+Approval+Pathway+for+Annamycin"
  ["blog_url"]=>
  string(218) "https://www.drugs.com/clinical_trials/moleculin-files-fda-expedited-approval-pathway-annamycin-18088.html?utm_source=ddc&utm_medium=rss&utm_campaign=Moleculin+Files+with+FDA+for+Expedited+Approval+Pathway+for+Annamycin"
  [15]=>
  string(19) "2019-03-14 06:03:41"
  ["add_date"]=>
  string(19) "2019-03-14 06:03:41"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5338"
  ["article_id"]=>
  string(4) "5338"
  [1]=>
  string(40) "EU Pharmaceutical Regulations & Strategy"
  ["article_title"]=>
  string(40) "EU Pharmaceutical Regulations & Strategy"
  [2]=>
  string(129) "This course will provide an up-to-date overview of the European pharmaceutical regulatory environment, procedures and obligations"
  ["short_description"]=>
  string(129) "This course will provide an up-to-date overview of the European pharmaceutical regulatory environment, procedures and obligations"
  [3]=>
  string(129) "This course will provide an up-to-date overview of the European pharmaceutical regulatory environment, procedures and obligations"
  ["description"]=>
  string(129) "This course will provide an up-to-date overview of the European pharmaceutical regulatory environment, procedures and obligations"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(72) "https://www.pharmiweb.com/event/eu-pharmaceutical-regulations-strategy-1"
  ["blog_url"]=>
  string(72) "https://www.pharmiweb.com/event/eu-pharmaceutical-regulations-strategy-1"
  [15]=>
  string(19) "2019-03-13 19:56:15"
  ["add_date"]=>
  string(19) "2019-03-13 19:56:15"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:28"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5279"
  ["article_id"]=>
  string(4) "5279"
  [1]=>
  string(43) " The Middle East Pharma Excellence Congress"
  ["article_title"]=>
  string(43) " The Middle East Pharma Excellence Congress"
  [2]=>
  string(162) "&#nl&#nl&#nl&#nlThe Middle East Pharma Excellence Congress is the premier platform for the pharmaceutical industry and attracts senior local, regional and interna"
  ["short_description"]=>
  string(162) "&#nl&#nl&#nl&#nlThe Middle East Pharma Excellence Congress is the premier platform for the pharmaceutical industry and attracts senior local, regional and interna"
  [3]=>
  string(517) "&#nl&#nl&#nl&#nlThe Middle East Pharma Excellence Congress is the premier platform for the pharmaceutical industry and attracts senior local, regional and international leaders from the pharmaceutical industry and government representatives to discuss key issues facing the pharmaceutical industry through a number of interactive presentations, panel discussions and on-stage interviews.&#nl &#nlDelegates will have the opportunity to hear from leading experts from across the region and the globe who will discuss..."
  ["description"]=>
  string(517) "&#nl&#nl&#nl&#nlThe Middle East Pharma Excellence Congress is the premier platform for the pharmaceutical industry and attracts senior local, regional and international leaders from the pharmaceutical industry and government representatives to discuss key issues facing the pharmaceutical industry through a number of interactive presentations, panel discussions and on-stage interviews.&#nl &#nlDelegates will have the opportunity to hear from leading experts from across the region and the globe who will discuss..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(74) "https://www.pharmiweb.com/event/the-middle-east-pharma-excellence-congress"
  ["blog_url"]=>
  string(74) "https://www.pharmiweb.com/event/the-middle-east-pharma-excellence-congress"
  [15]=>
  string(19) "2019-03-13 19:48:43"
  ["add_date"]=>
  string(19) "2019-03-13 19:48:43"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:28"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2018"
  ["article_id"]=>
  string(4) "2018"
  [1]=>
  string(102) "Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant"
  ["article_title"]=>
  string(102) "Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant"
  [2]=>
  string(150) "NEW HAVEN, Conn., March 13, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company"
  ["short_description"]=>
  string(150) "NEW HAVEN, Conn., March 13, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company"
  [3]=>
  string(242) "NEW HAVEN, Conn., March 13, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and..."
  ["description"]=>
  string(242) "NEW HAVEN, Conn., March 13, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(285) "https://www.drugs.com/clinical_trials/biohaven-announces-completion-pre-nda-meeting-fda-oral-cgrp-receptor-antagonist-rimegepant-18098.html?utm_source=ddc&utm_medium=rss&utm_campaign=Biohaven+Announces+Completion+of+Pre-NDA+Meeting+With+FDA+for+Oral+CGRP+Receptor+Antagonist+Rimegepant"
  ["blog_url"]=>
  string(285) "https://www.drugs.com/clinical_trials/biohaven-announces-completion-pre-nda-meeting-fda-oral-cgrp-receptor-antagonist-rimegepant-18098.html?utm_source=ddc&utm_medium=rss&utm_campaign=Biohaven+Announces+Completion+of+Pre-NDA+Meeting+With+FDA+for+Oral+CGRP+Receptor+Antagonist+Rimegepant"
  [15]=>
  string(19) "2019-03-13 12:03:23"
  ["add_date"]=>
  string(19) "2019-03-13 12:03:23"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1917"
  ["article_id"]=>
  string(4) "1917"
  [1]=>
  string(133) "Stokes Healthcare Inc. Issues Voluntary Nationwide Recall of Pilocarpine 0.1% Ophthalmic Solution Due to a High Level of Preservative"
  ["article_title"]=>
  string(133) "Stokes Healthcare Inc. Issues Voluntary Nationwide Recall of Pilocarpine 0.1% Ophthalmic Solution Due to a High Level of Preservative"
  [2]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy Stokes Healthcare Inc. is voluntarily recalling 1 lot of 81 units of Pilocarpine 0.1% Ophthalmic Sol"
  ["short_description"]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy Stokes Healthcare Inc. is voluntarily recalling 1 lot of 81 units of Pilocarpine 0.1% Ophthalmic Sol"
  [3]=>
  string(249) "Audience: Consumer, Health Professional, Pharmacy Stokes Healthcare Inc. is voluntarily recalling 1 lot of 81 units of Pilocarpine 0.1% Ophthalmic Solution, to the consumer and veterinarian office levels. The ophthalmic solution has been found to..."
  ["description"]=>
  string(249) "Audience: Consumer, Health Professional, Pharmacy Stokes Healthcare Inc. is voluntarily recalling 1 lot of 81 units of Pilocarpine 0.1% Ophthalmic Solution, to the consumer and veterinarian office levels. The ophthalmic solution has been found to..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(300) "https://www.drugs.com/fda/stokes-healthcare-inc-issues-voluntary-nationwide-recall-pilocarpine-0-1-ophthalmic-solution-due-14252.html?utm_source=ddc&utm_medium=rss&utm_campaign=Stokes+Healthcare+Inc.+Issues+Voluntary+Nationwide+Recall+of+Pilocarpine+0.1%25+Ophthalmic+Solution+Due+to+a+High+Level+of+"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/fda/stokes-healthcare-inc-issues-voluntary-nationwide-recall-pilocarpine-0-1-ophthalmic-solution-due-14252.html?utm_source=ddc&utm_medium=rss&utm_campaign=Stokes+Healthcare+Inc.+Issues+Voluntary+Nationwide+Recall+of+Pilocarpine+0.1%25+Ophthalmic+Solution+Due+to+a+High+Level+of+"
  [15]=>
  string(19) "2019-03-13 08:00:00"
  ["add_date"]=>
  string(19) "2019-03-13 08:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:50"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1944"
  ["article_id"]=>
  string(4) "1944"
  [1]=>
  string(136) "Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia"
  ["article_title"]=>
  string(136) "Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia"
  [2]=>
  string(150) "TOKYO and STAMFORD, Conn. – March 12, 2019 – Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Imbrium Therapeutics L.P. (Imbriu"
  ["short_description"]=>
  string(150) "TOKYO and STAMFORD, Conn. – March 12, 2019 – Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Imbrium Therapeutics L.P. (Imbriu"
  [3]=>
  string(247) "TOKYO and STAMFORD, Conn. – March 12, 2019 – Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Imbrium Therapeutics L.P. (Imbrium Therapeutics), a clinical-stage biopharmaceutical company and operating subsidiary of Purdue..."
  ["description"]=>
  string(247) "TOKYO and STAMFORD, Conn. – March 12, 2019 – Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Imbrium Therapeutics L.P. (Imbrium Therapeutics), a clinical-stage biopharmaceutical company and operating subsidiary of Purdue..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(229) "https://www.drugs.com/nda/lemborexant_190312.html?utm_source=ddc&utm_medium=rss&utm_campaign=Eisai+and+Imbrium+Therapeutics+Announce+U.S.+FDA+Filing+Acceptance+of+New+Drug+Application+for+Lemborexant+for+the+Treatment+of+Insomnia"
  ["blog_url"]=>
  string(229) "https://www.drugs.com/nda/lemborexant_190312.html?utm_source=ddc&utm_medium=rss&utm_campaign=Eisai+and+Imbrium+Therapeutics+Announce+U.S.+FDA+Filing+Acceptance+of+New+Drug+Application+for+Lemborexant+for+the+Treatment+of+Insomnia"
  [15]=>
  string(19) "2019-03-13 06:03:57"
  ["add_date"]=>
  string(19) "2019-03-13 06:03:57"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:51"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:51"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2384"
  ["article_id"]=>
  string(4) "2384"
  [1]=>
  string(45) "Ensuring Adhesion for Medical Device Assembly"
  ["article_title"]=>
  string(45) "Ensuring Adhesion for Medical Device Assembly"
  [2]=>
  string(153) "&#nl        For medical devices such as catheters, syringes, vials, test tubes and injector pens, many manufacturers are turning to plastics that are for"
  ["short_description"]=>
  string(153) "&#nl        For medical devices such as catheters, syringes, vials, test tubes and injector pens, many manufacturers are turning to plastics that are for"
  [3]=>
  string(225) "&#nl        For medical devices such as catheters, syringes, vials, test tubes and injector pens, many manufacturers are turning to plastics that are formulated to resist harsh chemical and environmental conditions.&#nl      "
  ["description"]=>
  string(225) "&#nl        For medical devices such as catheters, syringes, vials, test tubes and injector pens, many manufacturers are turning to plastics that are formulated to resist harsh chemical and environmental conditions.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "99"
  ["rss_id"]=>
  string(2) "99"
  [14]=>
  string(88) "https://www.assemblymag.com/articles/94791-ensuring-adhesion-for-medical-device-assembly"
  ["blog_url"]=>
  string(88) "https://www.assemblymag.com/articles/94791-ensuring-adhesion-for-medical-device-assembly"
  [15]=>
  string(19) "2019-03-12 23:37:00"
  ["add_date"]=>
  string(19) "2019-03-12 23:37:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:42:22"
  ["create_at"]=>
  string(19) "2019-05-09 16:42:22"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}